PELD Score (Younger Than 12)

Why use it

The PELD score provides an objective, validated, and reproducible measure of short-term mortality risk in children with chronic liver disease, enabling equitable organ allocation based on medical urgency. Before PELD, allocation relied heavily on subjective assessments and waiting time, which disadvantaged the sickest children. The PELD score correlates strongly with 90-day waitlist mortality (C-statistic 0.74), giving clinicians a single number that summarizes hepatic and nutritional status. Understanding the PELD score helps hepatologists communicate prognosis to families, time inpatient admissions, and make clinical decisions around nutritional support, complication management, and transplant urgency.

About

The Pediatric End-Stage Liver Disease (PELD) score is the original validated mortality prediction model developed by McDiarmid and colleagues for children under 12 years with end-stage liver disease awaiting liver transplantation, published in Transplantation in 2002. The PELD score was derived to predict 90-day waitlist mortality using five variables: serum albumin (g/dL), total serum bilirubin (mg/dL), INR, age at listing (<1 year), and presence of growth failure (height or weight Z-score <−2 SD). The PELD formula produces a continuous score on a logarithmic scale; higher scores correspond to higher 90-day waitlist mortality and thus higher transplant urgency. PELD was adopted by UNOS/OPTN in 2002 as the primary pediatric liver allocation tool, replacing the previous Child-Pugh–based scoring system. This classic PELD formula (without creatinine) remains widely used and cited in the pediatric hepatology literature, and is the original formula from the 2002 validation study. UNOS subsequently updated the formula to include serum creatinine (see PELD Creatinine calculator). The score applies exclusively to children younger than 12 years at listing; children 12 years and older are allocated using the adult MELD score.

When to use

• Listing evaluation for liver transplant in children younger than 12 years
• Prognostic assessment of end-stage liver disease severity in pediatric patients
• Communication of transplant urgency with families and referring physicians
• Monitoring disease trajectory — serial PELD calculation at outpatient visits to detect rapid deterioration
• Historical comparison with pre-creatinine era literature and clinical trials
• Educational purposes — understanding the components of pediatric liver disease severity

Formula

Pearls & pitfalls

• Minimum values: total bilirubin ≥1.0 mg/dL, albumin ≥1.0 g/dL, INR ≥1.0 — values below these are capped at the minimum before applying the logarithm.
• Growth failure (Z-score <−2 SD for height or weight) is the only subjective variable in PELD — requires anthropometric measurement and age/sex-adjusted reference charts.
• The classic PELD formula does NOT include creatinine — for the updated UNOS/OPTN formula that includes creatinine, use the PELD Creatinine calculator.
• PELD correlates with disease severity but does NOT capture all prognostic factors: portal hypertension severity, nutritional status beyond growth failure, and disease-specific variables (hepatoblastoma, metabolic liver disease) may require exception PELD points.
• Children under 1 year at listing receive an additional 0.436 PELD points — this reflects the higher mortality risk and more rapid disease course in very young infants.
• Total bilirubin in neonatal/infant cholestatic liver disease (Alagille syndrome, biliary atresia) can be markedly elevated (>10–15 mg/dL) — the logarithmic transformation moderates the contribution of extremely high bilirubin values.
• INR in children with liver disease reflects synthetic function — it must be measured WITHOUT correction (do not use corrected INR or anti-Xa level).
• Biliary atresia is the most common indication for pediatric liver transplant worldwide — PELD score is used regardless of etiology.
• PELD is a dynamic score — disease can deteriorate rapidly in children, especially with intercurrent infection. Frequent reassessment is essential.

Next steps

PELD ≤10: Lower urgency. Medical management and close outpatient monitoring. Optimize nutrition (caloric supplementation, consider NG tube feeding). PELD 11–18: Moderate urgency. Close hepatology follow-up every 1–2 weeks. Serial labs. PELD 19–24: High urgency. Inpatient or intensive outpatient monitoring. Frequent UNOS score updates. PELD >24: Very high urgency. ICU-level consideration. Evaluate for UNOS Status 1A/1B (fulminant or rapidly deteriorating). Contact transplant center.

Evidence

McDiarmid SV et al. Development of a pediatric end-stage liver disease score to predict poor outcome in children awaiting liver transplantation. Transplantation. 2002;74(2):173-181. PMID:12151728. Derivation cohort: 794 pediatric liver candidates. C-statistic 0.74 for 90-day waitlist mortality. Variables: albumin, total bilirubin, INR, age at listing (<1 year), growth failure. Shneider BL et al. Pediatric hepatology outcomes, PELD score and liver transplantation: a multicenter study. Liver Transpl. 2012. OPTN policy adoption: July 2002.

References

1. McDiarmid SV et al. Development of a pediatric end-stage liver disease score to predict poor outcome in children awaiting liver transplantation. Transplantation. 2002;74(2):173-181. — link
2. Sundaram SS et al. PELD score and hepatic fibrosis in pediatric nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr. 2009;49(3):355-360. — link
3. Shneider BL et al. Pediatric liver transplantation for metabolic disease. Am J Transplant. 2007;7(8):2107-2113. — link
4. Kim WR et al. MELD and PELD: application of survival models to liver allocation. Liver Transpl. 2000;6(1):3-14. — link